ArQule Company Profile (NASDAQ:ARQL)

About ArQule

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARQL
  • CUSIP: 04269E10
Key Metrics:
  • Previous Close: $1.26
  • 50 Day Moving Average: $1.44
  • 200 Day Moving Average: $1.44
  • 52-Week Range: $1.13 - $2.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.53
  • P/E Growth: -0.76
  • Market Cap: $88.90M
  • Outstanding Shares: 71,118,000
  • Beta: 1.51
Profitability:
  • Net Margins: -296.69%
  • Return on Equity: -55.62%
  • Return on Assets: -43.73%
Debt:
  • Current Ratio: 4.51%
  • Quick Ratio: 4.51%
Additional Links:
Companies Related to ArQule:

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $2.50 (96.85% upside)

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50View Rating Details
12/27/2015Royal Bank of CanadaUpgradeBuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ArQule (NASDAQ:ARQL)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.09)($0.09)($0.09)
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 58.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline
News IconArQule, Inc. (ARQL) price reactions to earnings announcements - Post Analyst (NASDAQ:ARQL)
postanalyst.com - February 26 at 3:33 PM
News IconLooking at the Numbers for ArQule, Inc. (NASDAQ:ARQL) - SKV News (NASDAQ:ARQL)
skvnews.com - February 25 at 3:34 PM
News IconTrading Indicator Check on ArQule Inc (ARQL) - The Standard (NASDAQ:ARQL)
6milestandard.com - February 24 at 3:48 PM
News IconShare Watch: Examining the Levels for ArQule, Inc. (NASDAQ:ARQL) - Baldwin Journal (NASDAQ:ARQL)
baldwinjournal.com - February 24 at 3:48 PM
finance.yahoo.com logoArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017 (NASDAQ:ARQL)
finance.yahoo.com - February 24 at 12:37 PM
News IconArQule Inc. (NASDAQ:ARQL) Closed the Last Trading Session at $1.29 - The Newburgh Press (NASDAQ:ARQL)
newburghpress.com - February 23 at 3:39 PM
News IconStock Price of ArQule, Inc. (ARQL) Decreases -13.67% - Money Flow Index & Trends (NASDAQ:ARQL)
www.moneyflowtrends.com - February 22 at 3:37 PM
News IconTivantinib misses OS endpoint in phase III liver cancer trial (NASDAQ:ARQL)
www.bioworld.com - February 21 at 3:54 PM
News IconArQule, Inc. (ARQL) Analyst Opinion And Outlook - Post Analyst (NASDAQ:ARQL)
postanalyst.com - February 21 at 8:59 AM
investopedia.com logoArQule Liver Cancer Drug Fails Phase 3 (ARQL) (NASDAQ:ARQL)
www.investopedia.com - February 20 at 3:32 PM
investopedia.com logoArQule Liver Cancer Drug Fails Phase 3 Trial (NASDAQ:ARQL)
www.investopedia.com - February 20 at 3:32 PM
News IconArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next? (NASDAQ:ARQL)
feedproxy.google.com - February 20 at 11:16 AM
marketexclusive.com logoArQule, Inc. (NASDAQ:ARQL)'s Liver Cancer Drug Fails: What's Next? - Market Exclusive (NASDAQ:ARQL)
marketexclusive.com - February 20 at 8:23 AM
News IconShares in Focus: ArQule, Inc. (NASDAQ:ARQL) – SKV News - SKV News (NASDAQ:ARQL)
skvnews.com - February 18 at 3:35 PM
News IconThe Top Three Holders Of ArQule, Inc. (ARQL) - Post Analyst (NASDAQ:ARQL)
postanalyst.com - February 18 at 3:35 PM
streetinsider.com logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses ... - StreetInsider.com (NASDAQ:ARQL)
www.streetinsider.com - February 18 at 3:35 PM
streetinsider.com logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses Primary Endpoint (NASDAQ:ARQL)
www.streetinsider.com - February 18 at 9:50 AM
seekingalpha.com logoArQule, Inc. (ARQL) (NASDAQ:ARQL)
seekingalpha.com - February 18 at 9:50 AM
us.rd.yahoo.com logoDaiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma (NASDAQ:ARQL)
us.rd.yahoo.com - February 18 at 9:50 AM
us.rd.yahoo.com logo6:02 am ArQule and Daiichi Sankyo (DSNKY (NASDAQ:ARQL)
us.rd.yahoo.com - February 18 at 9:50 AM
biz.yahoo.com logoARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ARQL)
us.rd.yahoo.com - February 18 at 9:50 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Banks, Kraft, Mondelez ... - Nasdaq (NASDAQ:ARQL)
www.nasdaq.com - February 17 at 6:24 PM
News IconShares in Focus: ArQule, Inc. (NASDAQ:ARQL) - SKV News (NASDAQ:ARQL)
skvnews.com - February 17 at 6:24 PM
smarteranalyst.com logoArQule, Inc. (ARQL) Shares Dive as HCC Trial Fails to Meet Primary Endpoint - Smarter Analyst (NASDAQ:ARQL)
www.smarteranalyst.com - February 17 at 6:24 PM
News IconTrading Desk: What are the Numbers Saying About ArQule, Inc. (NASDAQ:ARQL) - Piedmont Register (NASDAQ:ARQL)
piedmontregister.com - February 16 at 3:42 PM
News IconArQule, Inc. (ARQL) Broker Views On Wall Street - NewsDen (NASDAQ:ARQL)
newsden.net - February 16 at 8:33 AM
News IconInvestors are Following Shares of ArQule, Inc. (NASDAQ:ARQL ... - Baxter Review (NASDAQ:ARQL)
baxternewsreview.com - February 16 at 8:33 AM
News IconInvestor Center: Technical Watch for ArQule Inc. (ARQL) - Piedmont Register (NASDAQ:ARQL)
piedmontregister.com - February 8 at 3:51 PM
finance.yahoo.com logoArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017 (NASDAQ:ARQL)
finance.yahoo.com - February 8 at 3:51 PM
News IconReviewing Indicator Levels for ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - February 3 at 3:46 PM
News IconTechnical Trading: Focus on Shares of ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - February 2 at 8:39 PM
finance.yahoo.com logoArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher (NASDAQ:ARQL)
finance.yahoo.com - February 2 at 3:39 PM
News IconRunning on Fumes, Stock Loses Ground Mid-Session: ArQule, Inc. (NASDAQ:ARQL) - Wall Street Beacon (NASDAQ:ARQL)
wsbeacon.com - February 1 at 8:46 PM
News IconTrading Scope: ADX and CCI Review for ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - February 1 at 3:44 PM
News IconStock Dragging Lower Heading Into The Open: ArQule, Inc. (NASDAQ:ARQL) - Aiken Advocate (NASDAQ:ARQL)
aikenadvocate.com - February 1 at 3:44 PM
News IconVolatility Watch on Shares of ArQule, Inc. (NASDAQ:ARQL) - The Tribune (NASDAQ:ARQL)
lakecitytribune.com - January 31 at 3:49 PM
News IconIt Seems ArQule, Inc. (ARQL) Will Go Down. Formed A Few Months Bearish Double Bottom Pattern - The Randolph Guide (NASDAQ:ARQL)
randolphguide.com - January 31 at 3:49 PM
News IconStock ready to Pivot? Focus on Shares of ArQule, Inc. (NASDAQ:ARQL) - Prospect Journal (NASDAQ:ARQL)
prospectjournal.com - January 31 at 3:49 PM
News IconQuick Review on Trend Indicator Levels: ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - January 27 at 9:36 PM
News IconInvestor Watch: Volatility Review for ArQule, Inc. (NASDAQ:ARQL) - The Tribune (NASDAQ:ARQL)
lakecitytribune.com - January 26 at 8:57 PM
News IconWatching the Technicals on Shares of ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - January 25 at 3:44 PM
News IconEnlivened Volatility Spotted in Shares of ArQule, Inc. (NASDAQ:ARQL) - Wall Street Beacon (NASDAQ:ARQL)
wsbeacon.com - January 25 at 3:44 PM
News IconNew Analyst Ratings On ArQule, Inc. (ARQL) - NewsDen (NASDAQ:ARQL)
newsden.net - January 23 at 3:42 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: ArQule, Inc. (NASDAQ:ARQL) - Prospect Journal (NASDAQ:ARQL)
prospectjournal.com - January 23 at 3:42 PM
News IconPriming The Pump: Stock Volatility Spotted in ArQule, Inc. (NASDAQ:ARQL) - Wall Street Beacon (NASDAQ:ARQL)
wsbeacon.com - January 23 at 3:42 PM
News IconBargain or Bait? Stock Update on ArQule, Inc. (NASDAQ:ARQL) - Prospect Journal (NASDAQ:ARQL)
prospectjournal.com - January 21 at 2:45 AM
investornewswire.com logoArQule, Inc. (NASDAQ:ARQL) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ARQL)
www.investornewswire.com - January 20 at 4:40 PM
News IconTrading Corner: Eye on Technical Levels for ArQule Inc. (ARQL) - Sherwood Daily (NASDAQ:ARQL)
sherwooddaily.com - January 20 at 4:40 PM
News IconNotable Chart Action: Is Major Move Coming For ArQule, Inc. After This Double Bottom Pattern? - The Herald Beacon (NASDAQ:ARQL)
heraldbeacon.com - January 18 at 9:15 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: ArQule, Inc ... - Wall Street Beacon (NASDAQ:ARQL)
wsbeacon.com - January 15 at 8:36 PM

Social

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

Where is ArQule's stock going? Where will ArQule's stock price be in 2017?

1 brokers have issued 12 month target prices for ArQule's shares. Their predictions range from $2.50 to $2.50. On average, they anticipate ArQule's stock price to reach $2.50 in the next twelve months.

When will ArQule announce their earnings?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns ArQule stock?

ArQule's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.84%), FMR LLC (1.03%) and Dimensional Fund Advisors LP (0.15%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner.

Who sold ArQule stock? Who is selling ArQule stock?

ArQule's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ArQule stock cost?

One share of ArQule stock can currently be purchased for approximately $1.27.

ArQule (NASDAQ:ARQL) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

Earnings History Chart

Earnings by Quarter for ArQule (NASDAQ:ARQL)

Dividend History Chart

Dividend Payments by Quarter for ArQule (NASDAQ:ARQL)

Last Updated on 2/27/2017 by MarketBeat.com Staff